Figure 1.

Intratumoral immunotherapy agents control directly injected tumor lesions but not distantly engrafted tumors. MC38 tumor-bearing C57BL/6 mice were treated intratumorally with 50 μg of BO-112, 100 μg of STING ligand 5,6-dimethylxanthenone-4-acetic acid (DMXAA), 30 μg of anti-CD40, or 50 μg of toll-like receptor 9 agonists. Rat IgG/dimethyl sulfoxide/oligodeoxynucleotides control was used in control mice. (A) Schematic representation of the dosing time course and regimen followed for each treatment. (B) The tumor growth (mm³) is shown for each individual mouse in treated (upper panels) and untreated (lower panels) tumors. The numbers under each graph represent the fraction of mice that achieved complete tumor regression for each tumor type. (C) The average of in vivo tumor growth is shown for treated (left panel) and untreated (right panel) tumors. (D) The percentage of survival over time is shown for experiments in B. Data are representative of three independent experiments with six mice per group (mean±SEM). Two-way analyses of variance (ANOVAs) (C) or log-rank (D) tests were used to assess significance. Significant differences are displayed for comparisons of each group with the BO-112 group (**p<0.01, ***p<0.001, ****p<0.0001).